New gout drug epaminurad faces off against standard treatment in major trial
NCT ID NCT05815901
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tested a new drug called epaminurad against the standard gout medication febuxostat in 612 adults with gout. The goal was to see if epaminurad could lower uric acid levels more effectively and safely. The study is complete, but results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Epaminurad (a drug that lowers uric acid)
What this could lead to
If epaminurad works better than febuxostat, it could offer a new treatment option to control gout by lowering uric acid levels.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. Epaminurad may not be more effective or safer than existing drugs, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GOUT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Inha University Hospital
Incheon, South Korea